Welcome to our dedicated page for FOXO Technologies news (Ticker: $FOXO), a resource for investors and traders seeking the latest updates and insights on FOXO Technologies stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect FOXO Technologies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of FOXO Technologies's position in the market.
Rhea-AI Summary
FOXO Technologies Inc. plans to launch a new subscription-based, direct-to-consumer product offering that provides personalized health and wellness recommendations. The offering will combine FOXO's machine learning models, epigenetic biomarkers, and clinical data. The company has formed a collaboration with KR8.ai Inc. and secured an exclusive license to KR8's AI-based software to support the development and launch of the new offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.72%
Tags
-
Rhea-AI Summary
FOXO Technologies Inc. announces a 1-for-10 reverse stock split of its Class A common stock. The split will become effective on November 6, 2023, and trading on a split-adjusted basis will begin on November 7, 2023. The reverse stock split was approved by stockholders at the 2023 Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
FOXO Technologies Inc. announces completion of strategic review and provides business update on progress and plans. The new management team has initiated a significant restructuring of the business, including reducing headcount expenses by approximately 65% and divesting certain assets. The company is leveraging new AI technologies to enhance efficiency and drive a new direct-to-consumer go-to-market strategy. They have been granted two key patents that will be integrated into their new consumer-focused health and wellness offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
FOXO Technologies receives Issue Notification for key patent utilizing machine learning model to determine biochemical state and medical condition using DNA epigenetic data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.11%
Tags
-
Rhea-AI Summary
FOXO Technologies Inc. provides a letter to shareholders from the newly appointed interim CEO, Mark White, outlining the new direction for the company. The focus is on driving value through a more cost-effective go-to-market strategy, including a subscription-based app and AI technologies. The company is also exploring strategic alternatives and implementing initiatives to streamline costs and enhance the balance sheet.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.31%
Tags
-
Rhea-AI Summary
FOXO Technologies Inc.™ partners with Atrio Insurance/Singular Insurance Brokerage to expand distribution of its life insurance products
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.69%
Tags
Rhea-AI Summary
FOXO Technologies receives extension for compliance with NYSE American listing standards
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.35%
Tags
-
Rhea-AI Summary
FOXO Technologies Inc. received a notice from NYSE American for non-compliance with listing standards due to low stock price. The company must effect a reverse stock split or show sustained price improvement by February 16, 2024. Accelerated delisting action may be taken if stock trades at abnormally low levels. The company also submitted a plan to regain compliance with stockholders' equity requirement by December 12, 2024. The company's business, operations, and reporting requirements with the SEC are unaffected.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
FOXO Technologies advances in utilizing epigenetic biomarker technology and AI to promote optimal health and longevity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.72%
Tags
Rhea-AI Summary
FOXO Technologies Inc. (NYSEAM: FOXO) reported Q2 2023 financial results, focusing on capital structure streamlining, product expansion, and scientific discovery. The company completed two tender offers, raised $260,000 in a private placement, and launched Bioinformatics Services and Longevity Report™ beta product. Basic and diluted earnings per share increased, while adjusted EBITDA improved. The company will host a conference call and webcast today to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.84%
Tags
FOXO Technologies Inc.
NYSE:FOXO
FOXO Rankings
FOXO Stock Data
3.56M
4.46M
35.97%
4.16%
4.06%
Software Publishers
Information
United States of America
MINNEAPOLIS
About FOXO
formerly yousurance and life epigenetics. foxo bioscience is transforming the global longevity insurance industry with a next-generation underwriting protocol and consumer engagement platform based on epigenetic technology and insights. we also offer leading supervised machine learning and artificial intelligence technologies to identify epigenetic biomarkers that measure current states of health and aging.